T Powles1, J Brown2, J Larkin3, R Jones4, C Ralph5, R Hawkins6, S Chowdhury7, E Boleti8, A Bhal9, K Fife10, A Webb11, S Crabb12, T Geldart13, R Hill14, J Dunlop14, P E Hall15, D McLaren16, C Ackerman15, L Beltran15, P Nathan17. 1. Department of Medical Oncology, The Royal Free NHS Foundation Trust, London Barts Cancer Institute, CRUK Experiment Cancer Medicine Centre, London thomas.powles@bartshealth.nhs.uk. 2. Department of Medical Oncology, University of Sheffield, Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield Department of Medical Oncology, University of Leeds, Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire. 3. Department of Medical Oncology, The Royal Marsden Hospital, London. 4. The Beatson Cancer Centre, University of Glasgow, Glasgow. 5. Department of Medical Oncology, University of Leeds, Leeds Teaching Hospitals NHS Trust, Leeds, West Yorkshire. 6. Department of Medical Oncology, The Christie Hospital, Manchester. 7. Department of Medical Oncology, Guys and St Thomas' NHS Foundation Trust, London. 8. Department of Medical Oncology, The Royal Free NHS Foundation Trust, London. 9. Department of Oncology, University Hospital Bristol NHS Foundation trust, Bristol. 10. Addenbrooke's Cancer Centre, University of Cambridge, Cambridge. 11. Department of Medical Oncology, West Sussex Cancer Centre, Brighton. 12. Cancer Sciences Unit, Southampton NHS Foundation Trust, Southampton. 13. Department of Medical Oncology, Royal Bournemouth Hospital, Bournemouth. 14. Scottish Clinical Trials Research Unit (SCTRU), Partners in CaCTUS, Edinburgh. 15. Barts Cancer Institute, CRUK Experiment Cancer Medicine Centre, London. 16. Edinburgh Cancer Centre, Western General Hospital, Edinburgh. 17. Department of Medical Oncology, Mount Vernon Cancer Centre, Northwood, UK.
Abstract
BACKGROUND: Preclinical work suggests SRC proteins have a role in the development of resistance to vascular endothelial growth factor (VEGF) targeted therapy in metastatic clear-cell renal cancer (mRCC). This hypothesis was tested in this trial using the SRC inhibitor saracatinib and the VEGF inhibitor cediranib. PATIENTS AND METHODS: Patients with disease progression after ≥1 VEGF-targeted therapy were eligible to participate in this double-blind, randomized (1:1) phase II study. The study compared the combination cediranib 30 mg once daily (o.d.) and saracatinib 175 mg o.d. (CS) (n = 69) or cediranib 45 mg o.d. and placebo o.d. (C) (n = 69). Archived tissue was used for biomarker analysis [SRC, focal adhesion kinase (FAK), von Hippel-Lindau, protein tyrosine phosphatase 1b and hypoxia-inducible factor 2α : n = 86]. The primary end point was progression-free survival (PFS) by RECIST v1.1. RESULTS: Between 2010 and 2012, 138 patients were randomized across 16 UK sites. The characteristics of the two groups were well balanced. Partial responses were seen in 13.0% for C and 14.5% for CS (P > 0.05). There was no significant difference in PFS [5.4 months (3.6-7.3 months) for C and 3.9 (2.4-5.3 months) for CS; hazard ratio (HR) 1.18 (0.94-1.48)] or overall survival (OS) [14.2 months (11.2-16.8 months) for C and 10.0 (6.7-13.2 months) for CS; HR 1.28 (1.00-1.63)]. There was no significant difference in the frequency of key adverse events, dose reductions or drug discontinuations. None of the biomarkers were prognostic for PFS or OS. FAK overexpression correlated with an OS benefit [HR 2.29 (1.09-4.82), P > 0.05], but not PFS, for CS. CONCLUSIONS: Saracatinib did not increase the efficacy of a VEGF-targeted therapy (cediranib) in this setting. Biomarker analysis did not identify consistent predictive biomarkers. CLINICALTRIALSGOV: NCT00942877.
BACKGROUND: Preclinical work suggests SRC proteins have a role in the development of resistance to vascular endothelial growth factor (VEGF) targeted therapy in metastatic clear-cell renal cancer (mRCC). This hypothesis was tested in this trial using the SRC inhibitor saracatinib and the VEGF inhibitor cediranib. PATIENTS AND METHODS: Patients with disease progression after ≥1 VEGF-targeted therapy were eligible to participate in this double-blind, randomized (1:1) phase II study. The study compared the combination cediranib 30 mg once daily (o.d.) and saracatinib 175 mg o.d. (CS) (n = 69) or cediranib 45 mg o.d. and placebo o.d. (C) (n = 69). Archived tissue was used for biomarker analysis [SRC, focal adhesion kinase (FAK), von Hippel-Lindau, protein tyrosine phosphatase 1b and hypoxia-inducible factor 2α : n = 86]. The primary end point was progression-free survival (PFS) by RECIST v1.1. RESULTS: Between 2010 and 2012, 138 patients were randomized across 16 UK sites. The characteristics of the two groups were well balanced. Partial responses were seen in 13.0% for C and 14.5% for CS (P > 0.05). There was no significant difference in PFS [5.4 months (3.6-7.3 months) for C and 3.9 (2.4-5.3 months) for CS; hazard ratio (HR) 1.18 (0.94-1.48)] or overall survival (OS) [14.2 months (11.2-16.8 months) for C and 10.0 (6.7-13.2 months) for CS; HR 1.28 (1.00-1.63)]. There was no significant difference in the frequency of key adverse events, dose reductions or drug discontinuations. None of the biomarkers were prognostic for PFS or OS. FAK overexpression correlated with an OS benefit [HR 2.29 (1.09-4.82), P > 0.05], but not PFS, for CS. CONCLUSIONS: Saracatinib did not increase the efficacy of a VEGF-targeted therapy (cediranib) in this setting. Biomarker analysis did not identify consistent predictive biomarkers. CLINICALTRIALSGOV: NCT00942877.
Authors: Victoria K Woodcock; Sally Clive; Richard H Wilson; Vicky M Coyle; Michael R L Stratford; Lisa K Folkes; Richard Eastell; Claire Barton; Paul Jones; Shamim Kazmi-Stokes; Helen Turner; Sarah Halford; Adrian L Harris; Mark R Middleton Journal: Br J Cancer Date: 2018-02-13 Impact factor: 7.640
Authors: Stephan Ursprung; Helen Mossop; Ferdia A Gallagher; Evis Sala; Richard Skells; Jamal A N Sipple; Thomas J Mitchell; Anita Chhabra; Kate Fife; Athena Matakidou; Gemma Young; Amanda Walker; Martin G Thomas; Mireia Crispin Ortuzar; Mark Sullivan; Andrew Protheroe; Grenville Oades; Balaji Venugopal; Anne Y Warren; John Stone; Tim Eisen; James Wason; Sarah J Welsh; Grant D Stewart Journal: BMC Cancer Date: 2021-11-18 Impact factor: 4.430
Authors: Julia Rosemann; Lisa Müller; Jonas Weiße; Matthias Kappler; Alexander W Eckert; Markus Glaß; Danny Misiak; Stefan Hüttelmaier; Wolfgang G Ballhausen; Mechthild Hatzfeld; Monika Haemmerle; Tony Gutschner Journal: Mol Cancer Date: 2021-06-11 Impact factor: 27.401
Authors: Fabian Hofmann; Eu Chang Hwang; Thomas Bl Lam; Axel Bex; Yuhong Yuan; Lorenzo So Marconi; Börje Ljungberg Journal: Cochrane Database Syst Rev Date: 2020-10-14
Authors: Sarah Danson; Matthew R Mulvey; Lesley Turner; Janet Horsman; KJane Escott; Robert E Coleman; Sam H Ahmedzai; Michael I Bennett; David Andrew Journal: J Bone Oncol Date: 2019-09-18 Impact factor: 4.072